title: Possible reduction in indinavir serum concentrations by bosentan.
authors.forename: F
authors.initials: F
authors.lastname: Beau-Salinas
authors.forename: D
authors.initials: D
authors.lastname: Garot
authors.forename: C
authors.initials: C
authors.lastname: Le Guellec
authors.forename: A P
authors.initials: AP
authors.lastname: Jonville-Béra
authors.forename: V
authors.initials: V
authors.lastname: Ingremeau
authors.forename: E
authors.initials: E
authors.lastname: Autret-Leca
mesh_terms: D000328:Adult; D000959:Antihypertensive Agents / Q000494:pharmacology / Q000627:therapeutic use; D019540:Area Under Curve; D000077300:Bosentan; D004347:Drug Interactions; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy; D017320:HIV Protease Inhibitors / Q000493:pharmacokinetics / Q000627:therapeutic use; D006801:Humans; D006976:Hypertension, Pulmonary / Q000150:complications / Q000188:drug therapy; D019469:Indinavir / Q000097:blood* / Q000493:pharmacokinetics / Q000627:therapeutic use; D008297:Male; D008657:Metabolic Clearance Rate; D013449:Sulfonamides / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D000959:Antihypertensive Agents; D017320:HIV Protease Inhibitors; D013449:Sulfonamides; D019469:Indinavir; D000077300:Bosentan